Kantonsspital St.Gallen

Abbvie M16-852 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and

Andrea Rubbert Roth, Silvia Forrer, Carina Hutz, Mira Bartz Batliner & Thomas Neumann

abstract Giant Cell Arteritis: Phase 3 Safety and Efficacy Study of Upadacitinib in
Subjects with Giant Cell Arteritis
type of project clinical studies
status ongoing - recruiting phase
start of project 2019
end of project 2021
study design Study M16-852 is a Phase 3, global, multicenter, randomized, double-blind, PBO-controlled study.
Approximately 420 subjects will be enrolled into this study.
responsible person Andrea Rubbert-Roth